Bharat Immunologicals & Biologicals Corporation Limited announced earnings results for the third quarter ended December 31, 2020. For the third quarter, the company announced total revenue was INR 263.992 million compared to INR 289.551 million a year ago. Net loss was INR 18.947 million compared to INR 23.501 million a year ago. Basic loss per share from continuing operations was INR 0.44 compared to INR 0.54 a year ago. For the nine months, total revenue was INR 704.662 million. Net loss was INR 65.454 million. Basic loss per share from continuing operations was INR 1.52.